Validation of a Screening Tool for Social and Health Vulnerability in Pediatric Clinical Practice
NCT ID: NCT03640715
Last Updated: 2018-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2018-10-31
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The use of the Health Care Access Permanence Services (PASS) is intended to facilitate access to the health care system for people in precarious situations with care and social support within and outside the institutions. health.
The hypothesis tested is that the use of a formalized tool makes it possible to improve the detection of pediatric social vulnerability and to overcome reluctance to practice by a simple, rapid and justified approach with regard to ongoing care.
The primary objective is to validate a clinical tool for screening for pediatric social and health vulnerability - Tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
This multicenter cross-sectional validation study of the screening tool will be conducted in two SAUPs with a pediatric PASS.
1000 children will be included in the centers for a period of 1 year.
Following the introduction of the ENVU tool and after an expert interview, three groups of patients will be identified:
Group A: no vulnerability according to expert with no indication of any PASS marker care Group B: probable vulnerability according to the expert with indication of at least one PASS marker care Group C: high vulnerability according to the expert with indication of at least two care markers PASS Group B and C patients will be reviewed at 6 months for a second visit to the ENVU tool.
The main evaluation criterion will be the concordance between the indication of the use of the PASS by the "expert" PASS nurse (indicator of a significant social and health vulnerability) and the result of the ENVU tool.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Mobile App to Assist in Pediatric Triage
NCT05363124
iScreen Study: Best Methods for Social Screening in Pediatric Caregivers
NCT02197052
Social Navigation for Adolescents in ED
NCT03239041
Parental Compliance After Telephone Triage Advice During and After Confinement During the COVID-19 Epidemic in France
NCT04656444
Pediatric Virtual Visits as a Strategy for Access to Care During the COVID-19 Pandemic in a Pediatric Hospital
NCT04736680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The use of the Health Care Access Permanence Services (PASS) is intended to facilitate access to the health care system for people in precarious situations with care and social support within and outside the institutions. health.
The hypothesis tested is that the use of a formalized tool makes it possible to improve the detection of pediatric social vulnerability and to overcome reluctance to practice by a simple, rapid and justified approach with regard to ongoing care.
The primary objective is to validate a clinical tool for screening for pediatric social and health vulnerability - Tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
The secondary objectives will be to study the validity of the ENVU tool with regard to pathologies epidemiologically associated with social vulnerability: hypotrophy, prematurity, weight-loss disorders, school delay, asthma, skin infection, oral health, visual disturbances not treatment, delayed immunization, over-consumption of unscheduled care in SAUP, iron deficiency and lead poisoning (if research indicated by the reason for consultation). The illustration of the added value of the PASS care will be observed by a before-after study of the ENVU tool and the collected clinical data.
This multicenter cross-sectional validation study of the screening tool will be conducted in two SAUPs with a pediatric PASS.
1000 children will be included in the centers for a period of 1 year.
Following the introduction of the ENVU tool and after an expert interview, three groups of patients will be identified:
Group A: no vulnerability according to expert with no indication of any PASS marker care Group B: probable vulnerability according to the expert with indication of at least one PASS marker care Group C: high vulnerability according to the expert with indication of at least two care markers PASS Group B and C patients will be reviewed at 6 months for a second visit to the ENVU tool.
The main evaluation criterion will be the concordance between the indication of the use of the PASS by the "expert" PASS nurse (indicator of a significant social and health vulnerability) and the result of the ENVU tool.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group A
Group A: no vulnerability according to expert with no indication of any PASS marker care
ENVU
"ENfant VUlnerable": a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
group B
Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
ENVU
"ENfant VUlnerable": a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
group c
Group C: high vulnerability according to the expert with indication of at least two care markers PASS
ENVU
"ENfant VUlnerable": a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ENVU
"ENfant VUlnerable": a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* And consultant in the SAUP and PASS services investigators,
* And outside periods of custody and affluence,
* And accompanied by at least one parent or guardian
* And accepting to participate.
Exclusion Criteria
* Or Patient who has already consulted at PASS,
* Or child who has already participated in the study,
* Or in the absence of any parent (father or mother),
* Or current child protection measure - or evoked by doctors during the stay at SAUP,
* Or parents who do not speak French and can not translate at the moment of inclusion,
* Or inclusion of another child of the siblings,
* Or refusal of the child or parents,
* Or impossibility to organize an interview with an expert caregiver during the stay at the SAUP without prolonging it.
3 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EMILIE GARRIDO PRADALIE
Role: STUDY_DIRECTOR
APHM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Des Hopitaux de Marseille
Marseille, PACA, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Laporte R, Babe P, Jouve E, Daguzan A, Mazoue F, Minodier P, Noel G, Urbina D, Gentile S. Developing and Validating an Individual-Level Deprivation Index for Children's Health in France. Int J Environ Res Public Health. 2022 Dec 16;19(24):16949. doi: 10.3390/ijerph192416949.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.